Decision points to enter and exit the human cell cycle
进入和退出人体细胞周期的决策点
基本信息
- 批准号:9270039
- 负责人:
- 金额:$ 28.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-09 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:Alpha CellAntibodiesBackBindingBiochemicalBiosensorCCNE1 geneCell CycleCell Cycle RegulationCell modelCellsCommunitiesCyclin ADNA biosynthesisDataData AnalysesDecision MakingDegenerative DisorderDiseaseE2F transcription factorsE2F1 geneEventExperimental ModelsG1 PhaseGoalsGrowthGrowth FactorHourHumanImmune responseIndividualLaboratoriesLinkMalignant NeoplasmsMammalian CellMapsMeasurementMeasuresMediatingMessenger RNAMethodologyMethodsMitosisModelingMolecularMonitorNerve DegenerationNeurodegenerative DisordersOutcomePhosphotransferasesPopulationPost-Translational Protein ProcessingProcessProliferatingProteinsRampReporterS PhaseSignal TransductionSiteStimulusStressTestingTherapeuticTimeTissuesTranscriptional ActivationTreatment-Related CancerUp-RegulationWorkWound Healinganticancer researchbasecell typeimprovedpredictive modelingpublic health relevancerepairedresponsesingle cell analysistemporal measurementtissue degenerationtoolubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Diseases associated with cancer, immune responses, wound healing, and neurodegeneration are often caused by insufficient or excessive proliferation of particular human cell types. Under normal conditions, such cells have to robustly control if and when they proliferate to maintain and repair functioning tissues. While little is known about how cells exit the cell cycle, the decision to enter the cell cycle is often referred t as a "restriction point", a point where growth factors can be removed and cells still enter and complete the cell cycle. However, our recent single cell data analysis suggests that this fundamentally important decision is made by a different mechanism involving a cell cycle priming and a final cell cycle commitment step. Our proposed work will make use of automated single live cell and fixed cell analysis using biosensor and activity selective antibodies to measure key cell cycle regulatory events and to dissect the control circuits of cell cycle entry and exit. Our final goal is to develop and validate a quantitative model for cell cycle entry and exit. The outcome of the proposed work will be the identification, characterization and modeling of critical proliferation control points that can be exploited therapeutically to treat diseases suh as cancer, immune responses, wound healing, as well as neurodegenerative diseases. For many growth associated diseases, treatment will likely involve strategies to regulate the rate of proliferation of specific cell types. In addition, our work will provide the cell cycle and cancer research communities with experimental and modeling tools to investigate cell specific cell cycle control in different cell types.
描述(由申请人提供):与癌症、免疫反应、伤口愈合和神经变性相关的疾病通常是由特定人类细胞类型增殖不足或过度引起的。在正常情况下,此类细胞必须严格控制它们是否以及何时增殖。虽然人们对细胞如何退出细胞周期知之甚少,但进入细胞周期的决定通常被称为“限制点”,即生长因子可以被去除而细胞仍然进入并完成的点。细胞然而,我们最近的单细胞数据分析表明,这一至关重要的决定是通过涉及细胞周期启动和最终细胞周期承诺步骤的不同机制做出的,我们提出的工作将利用自动化的单活细胞和固定细胞分析。使用生物传感器和活性选择性抗体来测量关键的细胞周期调节事件并剖析细胞周期进入和退出的控制电路。我们的最终目标是开发和验证细胞周期进入和退出的定量模型。将是识别、表征和建模关键的增殖控制点可用于治疗癌症、免疫反应、伤口愈合以及神经退行性疾病等疾病,对于许多与生长相关的疾病,治疗可能涉及调节特定细胞类型的增殖速率的策略。此外,我们的工作将为细胞周期和癌症研究界提供实验和建模工具,以研究不同细胞类型中细胞特异性的细胞周期控制。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Putting the brakes on the cell cycle: mechanisms of cellular growth arrest.
抑制细胞周期:细胞生长停滞的机制。
- DOI:10.1016/j.ceb.2019.05.005
- 发表时间:2019-10-01
- 期刊:
- 影响因子:7.5
- 作者:Lindsey R. Pack;L. Daigh;T. Meyer
- 通讯作者:T. Meyer
Irreversible APC(Cdh1) Inactivation Underlies the Point of No Return for Cell-Cycle Entry.
不可逆的 APC(Cdh1) 失活是进入细胞周期的不归路的基础。
- DOI:
- 发表时间:2016-06-30
- 期刊:
- 影响因子:64.5
- 作者:Cappell, Steven D;Chung, Mingyu;Jaimovich, Ariel;Spencer, Sabrina L;Meyer, Tobias
- 通讯作者:Meyer, Tobias
Measuring Signaling and RNA-Seq in the Same Cell Links Gene Expression to Dynamic Patterns of NF-κB Activation.
在同一细胞中测量信号传导和 RNA 测序将基因表达与 NF-κB 激活的动态模式联系起来。
- DOI:10.1016/j.cels.2017.03.010
- 发表时间:2017-04-26
- 期刊:
- 影响因子:9.3
- 作者:Lane K;Van Valen D;DeFelice MM;Macklin DN;Kudo T;Jaimovich A;Carr A;Meyer T;Pe'er D;Boutet SC;Covert MW
- 通讯作者:Covert MW
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOBIAS MEYER其他文献
TOBIAS MEYER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOBIAS MEYER', 18)}}的其他基金
2011 Gradient Sensing and Directed Cell Migration Gordon Research Conference
2011 梯度传感和定向细胞迁移戈登研究会议
- 批准号:
8128064 - 财政年份:2011
- 资助金额:
$ 28.33万 - 项目类别:
Control of Hedgehog Signal Transduction by Neuropilin
Neuropilin 对 Hedgehog 信号转导的控制
- 批准号:
8620669 - 财政年份:2011
- 资助金额:
$ 28.33万 - 项目类别:
相似国自然基金
抗体依赖性增强效应介导非洲猪瘟病毒致病的分子机制
- 批准号:32373024
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
抗体修饰的靶向型MOF材料的构建及其诱导HER2阳性乳腺癌铜死亡协同效应的研究
- 批准号:52371256
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
抗猴痘病毒人源抗体的筛选及功能研究
- 批准号:32370992
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
AQP4抗体介导血小板炎症参与视神经脊髓炎器官局域免疫发生的机制研究
- 批准号:82371349
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
单核-巨噬细胞来源的LAMP3调控ROS通路参与抗MDA5抗体阳性皮肌炎肺间质纤维化机制研究
- 批准号:82302051
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Repurpose bone therapeutics for intervertebral disc degeneration in aged mice
重新利用骨疗法治疗老年小鼠椎间盘退变
- 批准号:
10709661 - 财政年份:2022
- 资助金额:
$ 28.33万 - 项目类别:
Repurpose bone therapeutics for intervertebral disc degeneration in aged mice
重新利用骨疗法治疗老年小鼠椎间盘退变
- 批准号:
10445485 - 财政年份:2022
- 资助金额:
$ 28.33万 - 项目类别:
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
用于治疗慢性乙型肝炎病毒感染的衣壳组装调节剂的临床前开发
- 批准号:
10257695 - 财政年份:2021
- 资助金额:
$ 28.33万 - 项目类别:
Protease Activated Bi-Specific Antibody Prodrugs for Efficient Transportation Across Blood-Brain Barrier
蛋白酶激活的双特异性抗体前药可有效跨血脑屏障运输
- 批准号:
10300356 - 财政年份:2021
- 资助金额:
$ 28.33万 - 项目类别:
Inhibition of TNF-alpha Signaling to Reduce Intervertebral Disc Inflammation
抑制 TNF-α 信号传导以减少椎间盘炎症
- 批准号:
10301274 - 财政年份:2021
- 资助金额:
$ 28.33万 - 项目类别: